ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,975.38
0.55%
Dow Jones
42,706.56
-0.06%
US Dollar vs MXN
20.343
0.04%
Brent Oil
76.115
0.00%
Bitcoin
102,127.38
-0.16%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) Noticias

Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc (RXRX)

NASDAQ
7.95
0.15
(1.92%)
Al cierre: 06 Enero 3:00PM
Delayed by 15 minutes
7.97
0.02
( 0.25% )
Fuera de horario: 6:02PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

RXRX Noticias

Solo noticias oficiales

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
1 hora hace
RXRX (1.92%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
1 hora hace
RXRX (1.92%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
1 hora hace
RXRX (1.92%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
26 Diciembre 2024
RXRX (1.92%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
20 Diciembre 2024
RXRX (1.92%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
18 Diciembre 2024
RXRX (1.92%)

Form 8-K - Current report
Edgar (US Regulatory)
17 Diciembre 2024
RXRX (1.92%)

Form 424B7 - Prospectus [Rule 424(b)(7)]
Edgar (US Regulatory)
17 Diciembre 2024
RXRX (1.92%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
11 Diciembre 2024
RXRX (1.92%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
10 Diciembre 2024
RXRX (1.92%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 Diciembre 2024
RXRX (1.92%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
05 Diciembre 2024
RXRX (1.92%)

RXRX Discussion

Ver más
bwrbad bwrbad 1 día hace
Gibson🤢🥵🥶😷Gibson
👍️0
bwrbad bwrbad 3 días hace
baby nvda
👍 1
bwrbad bwrbad 7 días hace
balding haircut at RXRX
👍️0
Monksdream Monksdream 2 semanas hace
RXRX, under $7
👍️0
bwrbad bwrbad 2 semanas hace
out for now, let CEO work his magic if he has one under his sleeve
👍️0
bwrbad bwrbad 3 semanas hace
is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.
👍️0
bwrbad bwrbad 3 semanas hace
RXRX
👍️0
bwrbad bwrbad 3 semanas hace
RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......
👍️0
bwrbad bwrbad 4 semanas hace
RxRx M&A: Valence –Cyclica - Exscientia
Valence – a leader in generative AI and deep learning models
Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
Exscientia - AI-driven precision medicine
RXRX - Regenerative AI - TechBio powerhouse
undergoing post merger reorganization, some job cuts
enough cash to fund through 2027
Ark Q3 2024 Stake: $215.9 million
Hedge Fund Investors Q3 2024:: 16
more than ten drugs in trials.
👍️0
bwrbad bwrbad 4 semanas hace
market up big and RxRx ignored,
if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.
👍️0
TucsonPhil TucsonPhil 4 semanas hace
RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.
👍️ 1
bwrbad bwrbad 4 semanas hace
Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
Shares Outstanding 6 388.94M; Float 8 252.42M
clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

% Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%
👍️ 1
JJ8 JJ8 4 semanas hace
Rxrx share price Long Tail Up since 06 Dec 2024.
👍️0
paperman paperman 4 semanas hace
Phase 1 news expected tonight at conference.
👍️0
paperman paperman 4 semanas hace
Phase 1 news expected tonight at conference.
👍️0
bwrbad bwrbad 4 semanas hace
this is one magnificent AI drug discovery platform - be household name like google tesla Microsoft ...
👍️0
JJ8 JJ8 1 mes hace
Bought it yesterday at $6.60

Today it's up about 22%.

Same story with 2 other stocks and they all go up today more than 20%!

Whoa! IN CREDIBLE!
👍️0
TucsonPhil TucsonPhil 1 mes hace
Agreed, but there will be wild swings, until they get their footing with clinical trials proving the concept works. Trade it until then, and keep one foot in the door for surprise announcements.
👍️0
bwrbad bwrbad 1 mes hace
RxRx going to be top player in future pharma drug discovery
👍️0
TucsonPhil TucsonPhil 1 mes hace
Good company, but MMs playing games this morning. Insider buying? News? Who knows? Missed this runup, but will wait for the dip again.
👍️0
bwrbad bwrbad 1 mes hace
GOOG -- RxRx -- NVDA -- RxRx -- MSFT
👍️0
bwrbad bwrbad 1 mes hace
agree but better, much bigger scope, on way to become a high flying company of the future
price target 150 in two year
👍️0
uksausage uksausage 1 mes hace
no it is the PLTR of Drug discovery
both rely on NVDA to run fast
👍️0
bwrbad bwrbad 1 mes hace
started buying little little- this is NVDA of DRUG DISCOVERY
👍️0
ToucanYoucan ToucanYoucan 1 mes hace
$RXRX - That's why I'm planning to steadily accumulate shares - with the hope that one or more of these new treatments materializes.
👍️0
bwrbad bwrbad 1 mes hace
high potential if delivers,
👍️0
TucsonPhil TucsonPhil 1 mes hace
Good gains in past week, but looks like it is getting ready to drift lower again.
👍️0
TucsonPhil TucsonPhil 1 mes hace
First patient dosed.

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-first-patient-dosed-phase-12-clinical-study
👍️0
lambchops lambchops 1 mes hace
Glad to see the uptick! Was beaten down for a while. Too good of stock to be down for long.

LC

RXRX
👍️ 1
ToucanYoucan ToucanYoucan 1 mes hace
$RXRX - Having a huge day here!!
👍️0
ToucanYoucan ToucanYoucan 1 mes hace
$RXRX - Nice move up today! This will take a little time to find its footing pps-wise after the merger...imo
👍️0
TucsonPhil TucsonPhil 2 meses hace
Many foreign countries supplying pharmaceuticals to U.S. at exorbitant markups.

Will anything be done about that? I do not believe tariffs will help with that problem, since people either pay, whatever the cost, or suffer and die.
👍️0
Monksdream Monksdream 2 meses hace
RXRX 10Q 11/6
👍️0
Monksdream Monksdream 2 meses hace
RXRX under $10
👍️0
Monksdream Monksdream 2 meses hace
RXRX under $10
👍️0
mick mick 3 meses hace
👍️0
abrooklyn abrooklyn 3 meses hace
https://x.com/RecursionPharma/status/1841453309342740925
👍️0
TucsonPhil TucsonPhil 3 meses hace
So many clinical trials in work, but for this to translate to value, they will need to show high efficacy and a much shorter time-to-market, using Recursion platform. The problem may be that Recursion can identify promising candidates quickly, but the slow-moving follow-on processes will still eat up valuable time. The value proposition here is the decrease in attrition, for candidates that fail in early stage trials.

https://ir.recursion.com/news-releases/news-release-details/recursion-gives-guidance-seven-clinical-readouts-within-18

https://www.recursion.com/pipeline
👍️0
mick mick 4 meses hace
WALL @ $7.5 , $7.0
👍️0
mick mick 4 meses hace
https://www.stockscores.com/charts/charts/?ticker=RXRX
👍️0
lambchops lambchops 4 meses hace
Yes. Good stock to put on watchlist IMO.
Still reasonably cheap. Check MACD.

LC

RXRX
👍️0
mick mick 4 meses hace
diamond in the ruff

RXRX
Recursion Pharmaceuticals Inc
6.32
0.20 (3.27%)
Volume: 3,082,418
Day Range: 6.055 - 6.32
Last Trade Time: 4:28:47 PM EDT
👍️0
mick mick 4 meses hace
RXRX
Recursion Pharmaceuticals Inc
5.95
-0.22 (-3.57%)
Volume: 4,577,882
Day Range: 5.895 - 6.30
Last Trade Time: 7:58:59 PM EDT
👍️0
lambchops lambchops 4 meses hace
Yes, I've been adding shares of RXRX this week.

LC

RXRX
👍️0
TucsonPhil TucsonPhil 4 meses hace
Looks.like a little dilution, but a good buying opportunity, to add some more.
👍️0
lambchops lambchops 4 meses hace
Judging on the reaction some investors must not have liked it either.Will be a strong company into RXRX.I like buying good companies that have a downdraft. They usually come back strong.
Please note I own shares in this company.

LC

RXRX
👍️0
TucsonPhil TucsonPhil 4 meses hace
I had not seen that merger announcement. Never came across in my broker news feed.
👍️0
lambchops lambchops 4 meses hace
Did you see the possible merger news?

LC

RXRX
👍️0
TucsonPhil TucsonPhil 4 meses hace
Running millions of tests per week, to find promising drug candidates.

What we do not know, is how many candidates have entered clinical trials.

When news pops about RXRX origination of promising cures, this will skyrocket.

Oops, missed this one:

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-phase-2-data-rec-994-first-disease
👍️0
lambchops lambchops 4 meses hace
Looks ready to move IMO.

LC

RXRX
👍️0

Su Consulta Reciente

NASDAQ
RXRX
Recursion Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados